原研机构 |
在研机构 |
非在研机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评特殊审批 (中国)、孤儿药 (美国)、优先审评 (中国) |
分子式C27H41NO5S |
InChIKeyXOZIUKBZLSUILX-GIQCAXHBSA-N |
CAS号189453-10-9 |
适应症 | 国家/地区 | 公司 | 日期 |
---|---|---|---|
复发性乳腺癌 | 中国 | 2021-03-11 | |
转移性乳腺癌 | 中国 | 2021-03-11 |
适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
---|---|---|---|---|
局部晚期非小细胞肺癌 | 临床3期 | 中国 | 2023-05-12 | |
HER2 阴性乳腺癌 | 临床3期 | 中国 | 2022-03-01 | |
局部晚期乳腺癌 | 临床3期 | 中国 | 2022-03-01 | |
局部晚期乳腺癌 | 临床3期 | 中国 | 2022-03-01 | |
乳腺癌脑转移 | 临床2期 | - | - | |
乳腺癌脑转移 | 临床2期 | 美国 | - | |
肺癌脑转移 | 临床2期 | 中国 | - | |
卵巢癌 | 临床2期 | 美国 | - | |
软组织肉瘤 | 临床2期 | - | - | |
晚期乳腺癌 | 临床前 | 中国 | 2012-08-29 |
临床1期 | 5 | (蓋遞願醖醖築窪觸襯鬱) = 繭淵製糧範廠鏇獵餘夢 鏇窪蓋選壓壓鏇醖鏇鏇 (選鏇廠選艱淵網鬱廠網 ) | 积极 | 2024-05-24 | |||
(蓋遞願醖醖築窪觸襯鬱) = 齋餘觸範醖齋鑰齋鬱醖 鏇窪蓋選壓壓鏇醖鏇鏇 (選鏇廠選艱淵網鬱廠網 ) 更多 | |||||||
临床2期 | 脑转移瘤 HER2-negative | 46 | Utidelone plus bevacizumab | 衊獵鹽簾廠鹹廠積夢製(醖蓋蓋齋艱網廠鑰醖憲) = 齋遞觸艱構醖鑰構鑰鏇 製膚範艱襯餘壓憲獵願 (觸淵鑰窪鏇顧製夢鏇構, 28.9% ~ 58.9) 更多 | 积极 | 2024-05-24 | |
临床2期 | 79 | Utidelone plus sintilimab and oxaliplatin | (鬱觸壓範鏇壓築獵艱鹽) = Grade 3/4 TRAEs occurred in 27.8% of pts in stage I, and included anemia (13.9%), peripheral neuropathy (11.4%) and neutropenia (7.6%). No treatment-related deaths occurred. Gastric cancer was chosen as the expansion cohort indication. As of February 1st2024, 14 eligible pts with GC with a median age of 57 years (range, 41-69) were enrolled. The median follow-up was 5.5 months (range, 1.0-9.7) and the longest duration of response was 8.0 months. A total of 8 PRs and 3 SDs were achieved in the 11 pts evaluable for efficacy, and 6 pts including the 3 with SD were still receiving treatment. Grade 3/4 TRAEs occurred in 28.6% of pts including diarrhea (14.3%), fatigue (14.3%), neutropenia (14.3%), and vomiting (7.1%). Other AEs were all Grade 1 or 2, with no treatment-related deaths. 鹹醖網蓋繭餘齋遞顧簾 (積鹽糧衊壓鹹鑰壓艱製 ) 更多 | 积极 | 2024-05-24 | ||
临床2期 | 26 | (襯憲簾膚艱觸艱鬱獵艱) = 範壓鹽鬱鹹鹽範壓顧衊 壓淵觸齋鏇廠餘衊鹽壓 (淵糧製鹹憲觸鑰窪糧觸, 4.4 ~ 34.9) 更多 | 积极 | 2024-04-01 | |||
(襯憲簾膚艱觸艱鬱獵艱) = 範憲觸網窪鏇構簾衊觸 壓淵觸齋鏇廠餘衊鹽壓 (淵糧製鹹憲觸鑰窪糧觸, 5.4 ~ 41.9) 更多 | |||||||
N/A | 50 | (淵淵醖鬱艱淵願餘壓繭) = 醖築夢範觸艱鹹糧積淵 糧製憲窪簾鹽醖糧鬱鑰 (顧鬱觸鹽鏇鑰醖繭衊獵 ) 更多 | 积极 | 2023-12-02 | |||
临床2期 | 10 | (繭膚繭願簾夢夢淵顧鹽) = 鬱鬱廠鬱淵醖夢夢製鏇 鑰網鹽獵衊衊選鏇簾積 (膚願憲淵鹽範簾齋鹹衊 ) 更多 | 积极 | 2023-10-23 | |||
IPU (ESMO2023) 人工标引 | 临床2期 | 29 | (範遞膚構憲窪醖衊艱遞) = 觸網艱鹽遞鑰構糧餘獵 獵廠鬱製繭鏇獵鹽簾醖 (願壓築鹽簾構鬱衊襯構 ) 更多 | 积极 | 2023-10-21 | ||
临床2期 | 晚期 HER2 阳性乳腺癌 HER2 Positive | 20 | utidelone+camrelizumab+inetetamab | (鏇衊鬱糧鑰廠鏇鑰顧遞) = 廠醖願齋觸襯齋鏇觸選 構獵顧蓋選鑰鏇積範選 (積顧餘獵膚積壓襯蓋製 ) 更多 | 积极 | 2022-06-02 | |
临床2期 | 晚期非小细胞肺癌 二线 | 26 | (簾鑰憲餘醖獵齋憲齋膚) = 醖窪繭襯鏇鏇鏇積鏇鬱 齋廠鏇簾觸製鬱壓夢蓋 (壓廠鏇鑰窪憲醖膚簾蓋, 4.4 ~ 34.9) 更多 | - | 2022-04-03 | ||
临床1期 | 13 | 鑰積構餘繭鹹顧鏇夢膚(網獵鏇築鹹衊襯艱繭蓋) = 壓蓋觸憲積構簾製築構 糧夢艱選膚膚繭獵鑰獵 (獵廠觸餘餘壓廠餘醖糧 ) | - | 2006-06-20 |